85 results on '"Dieterich D"'
Search Results
2. PIN8 HEPATITIS B TREATMENT PATTERNS IN US CLINICAL CARE FOLLOWING TENOFOVIR ALAFENAMIDE (TAF) APPROVAL
3. Urethane-based dispersions
4. PIN26 COST-MINIMIZATION ANALYSIS OF PAN-GENOTYPIC TREATMENT REGIMENS FOR CHRONIC HEPATITIS C
5. PIN9 CLINICAL PRACTICE EXPERIENCE WITH TENOFOVIR ALAFENAMIDE (TAF) FOR TREATMENT OF HEPATITIS B IN THE US
6. Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients
7. Real‐world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta‐analysis
8. A systematic model improves hepatitis C virus birth cohort screening in hospital-based primary care
9. Utilization of DAA therapies ledipasvir/sofosbuvir and sofosbuvir/ velpatasvir in patients with genotype 1 HCV: real-world experience from the TRIO Network
10. Elbasvir/Grazoprevir effectiveness in patients with Chronic Hepatitis C and Chronic Kidney Disease: real-world experience from the TRIO Network
11. Real-world treatment utilization and results in the renaissance of HCV Care: analyses of treatment for 7,550 Patients from the TRIO Network
12. Utilization of sofosbuvir/velpatasvir in genotype 2–6 HCV: real-world experience from the TRIO network
13. Real-world use of elbasvir/grazoprevir and outcomes in patients with chronic hepatitis C: retrospective data analyses from the TRIO Network
14. Real‐world effectiveness for 12 weeks of ledipasvir–sofosbuvir for genotype 1 hepatitis C: the Trio Health study
15. EFFECTIVENESS OF 12 OR 24 WEEK LDV/SOF AND 12 WEEK LDV/SOF+RBV IN TREATMENT-EXPERIENCED PATIENTS WITH CIRRHOTIC, GENOTYPE 1 HEPATITIS C: REAL-WORLD EXPERIENCE FROM THE TRIO NETWORK
16. EFFECTIVENESS OF 8 OR 12 WEEK LDV/SOF IN TREATMENT-NAÏVE PATIENTS WITH NON-CIRRHOTIC, GENOTYPE 1 HEPATITIS C: REAL-WORLD EXPERIENCE FROM THE TRIO NETWORK
17. High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV-infected patients treated with sofosbuvir-containing regimens
18. Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network
19. Ledipasvir/Sofosbuvir+/−Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the Trio Network
20. No Effect of Proton Pump Inhibitor (PPI) Use on SVR with Ledipasvir/Sofosbuvir (LDV/SOF): Real World Data from 2034 Genotype 1 Patients in the Trio Network
21. Ledipasvir/Sofosbuvir ± Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous Population from the Trio Network
22. LP01 : Daclatasvir plus sofosbuvir for treatment of HCV genotypes 1-4 in HIV-HCV coinfection: The ALLY-2 study
23. P0867 : Efficacy evaluation of 24 week SOF + RBV in a heterogeneous, real-world population of genotype 3 HCV patients; Data from the trio network
24. P0775 : Final evaluation of 955 HCV patients treated with 12 week regimens containing sofosbuvir +/- simeprevir in the trio network: Academic and community treatment of a real-world, heterogeneous population
25. P0787 : Comparison of sofosbuvir +/- simeprevir in heterogeneous, real-world populations of HCV patients over 70 years of age vs younger HCV patients; Data from the Trio network
26. P1353 : A single tablet regimen of ledipasvir/sofosbuvir for 12 weeks in HCV genotype 1 or 4 infected patients with HIV-1 co-infection : The phase 3 ION-4 study
27. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection
28. Telaprevir Activity in Treatment-Naive Patients Infected With Hepatitis C Virus Genotype 4
29. COL01-03: PHOTON-1 : association sofosbuvir-ribavirine pour l’infection à VHC de génotypes 1 à 3 chez des patients co-infectés par le VIH
30. P1173 THE IMPACT OF HIV CO-INFECTION ON RATES AND SEVERITY OF ANEMIA OCCURRING DURING TREATMENT WITH SOFOSBUVIR-CONTAINING HCV REGIMENS: A POOLED ANALYSIS
31. P1157 IMPACT OF BASELINE VARIABLES ON RESPONSE TO FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN PATIENTS WITH HIV/HCV GENOTYPE-1 COINFECTION IN A PHASE III TRIAL
32. P1125 PHARMACOKINETIC-RESPONSE ANALYSIS OF FALDAPREVIR IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION: A POOLED ANALYSIS OF TWO PHASE III TRIALS
33. P1122 COMPARISONS OF POPULATIONS IN FALDAPREVIR PHASE III STUDIES BASED ON PEGYLATED INTERFERON a-2a AND RIBAVIRIN-PREDICTED RESPONSIVENESS AND IMPACT ON ACHIEVING SVR12
34. P1129 EFFECT OF HCV GENOTYPE-1 SUBTYPE ON RESPONSE TO FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: POOLED DATA FROM PHASE III TRIALS
35. P1131 SIMILAR ADJUSTED SVR12 RATES FOR HIV CO-INFECTED AND HCV MONO-INFECTED PATIENTS AND NO DOSE OR POPULATION (TREATMENT-NAIVE/RELAPSER) EFFECT: POOLED ANALYSIS OF FALDAPREVIR PHASE III TRIALS
36. P1227 FALDAPREVIR EFFICACY IN HCV GENOTYPE-1-INFECTED PATIENTS IN FOUR PHASE 3 TRIALS: ANALYSIS BY NS3 BASELINE POLYMORPHISMS, GENOTYPE-1 SUBTYPE AND GENOTYPE-1A CLADES
37. P1121 EARLY STOPPING RULES FOR FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: EXPLORATORY STUDY OF POOLED DATA FROM PHASE III TRIALS
38. P1133 COMPARISON OF 24 AND 48 WEEKS OF TREATMENT WITH FALDAPREVIR AND PEGYLATED INTERFERON/RIBAVIRIN IN PATIENTS WITH DETECTABLE BUT NOT QUANTIFIABLE HCV RNA AT WEEK 4
39. Commentary: real-world triple therapy experience treating hepatitis C virus - authors' reply
40. Faldaprevir plus pegyliertes Interferon alpha-2a und Ribavirin (PR) bei Patienten mit HIV und Hepatitis C Genotyp (GT)-1 Koinfektion: End of Treatment Response (ETR) – Ergebnisse der Phase III Studie STARTVerso 4
41. Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir
42. When Treatment Is Mitigated by Adverse Events: The Economic Impact of Treatment-Associated Adverse Events in Cirrhotic Non-Responders Treated with Boceprevir or Telaprevir and Peginterferon Alpha/Ribavirin
43. HIV/Hepatitis C Virus-Coinfected Patients and Cirrhosis: How to Diagnose It and What to Do Next?
44. Clinical Factors That Predict Noncirrhotic Portal Hypertension in HIV-Infected Patients: A Proposed Diagnostic Algorithm
45. 1220 TRIPLE COMBINATION THERAPY FOR HEPATITIS C WITH TELAPREVIR EXHIBITS GREATER EARLY ANTIVIRAL SUPPRESSION THAN WITH BOCEPREVIR REGARDLESS HIV STATUS
46. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents
47. Early-Onset Liver Fibrosis Due to Primary Hepatitis C Virus Infection Is Higher Over Time in HIV-Infected Men
48. 10 PEGINTERFERON LAMBDA-1A (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPES (G) 2 OR 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB
49. 1367 NONCIRRHOTIC PORTAL HYPERTENSION (NCPH) IN HIV-INFECTED PATIENTS: A CASE CONTROL STUDY
50. 1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.